Doxy.me vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 39)
Doxy.me logo

Doxy.me

EmergingHealthcare

Telehealth

1M+ clinicians 150+ countries; 250K active providers; $50.2M revenue; acquired Telehealth.org/TeleMental Health Institute 2025; TIME HealthTech 2025; Ventures fund; telemedicine leader

AI VisibilityBeta
Overall Score
D39
Category Rank
#415 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
44
Gemini
39

About

Doxy.me was founded in 2013 by Brandon Welch in Hawaii with a mission to make telehealth accessible to every clinician and patient, regardless of technical sophistication or budget. The platform was built as a browser-based, zero-download video conferencing solution designed specifically for healthcare — requiring no app installation for patients and offering HIPAA-compliant video sessions out of the box. This simplicity-first approach drove grassroots adoption among solo practitioners and small clinics.\n\nDoxy.me's platform provides HIPAA-compliant video visits, virtual waiting rooms, patient intake forms, group rooms, and integrations with major EHR and practice management systems. Its free tier has been instrumental in driving adoption among independent clinicians who need compliant telehealth without enterprise procurement cycles. Premium tiers add advanced features including custom branding, staff accounts, and analytics. In 2025, Doxy.me acquired Telehealth.org and the TeleMental Health Institute, expanding its educational resources and professional training offerings.\n\nDoxy.me has grown to serve 1M+ clinicians across 150+ countries, with 250,000 active providers using the platform regularly. The company reported $50.2M in annual revenue and was recognized on TIME's HealthTech 2025 list. Its combination of clinical accessibility, global reach, and a freemium model that converts at scale positions Doxy.me as a foundational layer of the global telehealth infrastructure — particularly for solo and small-group practices that larger enterprise platforms overlook.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#415
Category Rank
#2
81
AI Consensus
83
stable
Trend
up
36
ChatGPT
92
44
Perplexity
93
39
Gemini
89
37
Claude
96
38
Grok
95

Key Details

Category
Telehealth
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Doxy.me
Telehealth

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.